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Abstract
Background: Phase II cancer studies are undertaken to assess the activity of a new drug or a new
treatment regimen. Activity is sometimes defined in terms of a survival probability, a binary
outcome such as one-year survival that is derived from a time-to-event variable. Phase II studies
are usually designed with an interim analysis so they can be stopped if early results are
disappointing. Most designs that allow for an interim look are not appropriate for monitoring
survival probabilities since many patients will not have enough follow-up by the time of the interim
analysis, thus necessitating an inconvenient suspension of accrual while patients are being followed.
Methods:  Two-stage phase II clinical trial designs are developed for evaluating survival
probabilities. These designs are compared to fixed sample designs and to existing designs developed
to monitor binomial probabilities to illustrate the expected reduction in sample size or study length
possible with the use of the proposed designs.
Results: Savings can be realized in both the duration of accrual and the total study length, with the
expected savings increasing as the accrual rate decreases. Misspecifying the underlying survival
distribution and the accrual rate during the planning phase can adversely influence the operating
characteristics of the designs.
Conclusion: Two-stage phase II trials for assessing survival probabilities can be designed that do
not require prolonged suspension of patient accrual. These designs are more efficient than single
stage designs and more practical than existing two-stage designs developed for binomial outcomes,
particularly in trials with slow accrual.
Background
Phase II clinical trials are usually conducted to assess the
activity of a new drug or treatment regimen. Activity in
many phase II cancer trials is quantified by tumor re-
sponse, and a treatment is considered successful for an in-
dividual patient if his or her tumor burden is reduced by
50% or more. Here, the response rate is the number of pa-
tients responding divided by the total number of evalua-
ble patients. In other trials, activity might be quantified by
a time to event variable such as remission-free or overall
survival, and the outcome might be the proportion of pa-
tients remission-free or alive at one or two years. Regi-
mens showing sufficient activity in the phase II setting
might be evaluated subsequently in a phase III compara-
tive trial. Phase II trials typically test the null hypothesis
H0: p ≤ p0 that the true response rate of the treatment un-
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der consideration is less than some level (p0) that would
be deemed too low for further consideration. Studies are
designed so that the probability of falsely rejecting H0
(i.e., considering the treatment worthy of further
investigation when in fact it is not) is α and the probabil-
ity of rejecting H0 when p = p1 (i.e., considering the drug
worthy of further investigation when in fact it is) is 1-β.
Due to ethical concerns, interim analyses are done in
phase II trials to ensure that patients are not receiving a
treatment that is clearly inferior to other available op-
tions. Usually these trials are not stopped early when a
treatment has shown better than expected activity because
there is no ethical dilemma, and there is usually interest
in obtaining better estimates of the treatment's activity.
On the other hand, if the treatment is performing poorly,
physicians want to explore other options for subsequent
patients. Numerous frequentist and Bayesian multi-stage
phase II designs have been developed for monitoring bi-
nary outcomes [see, for example, [1–10]]. Simon [4] de-
veloped two-stage plans that minimized the maximum
expected sample size and plans that minimized the ex-
pected sample size under the null hypothesis. He felt one
interim analysis was usually sufficient since it is frequently
impractical to analyze the data multiple times, and two-
stage designs realize much of the savings possible with se-
quential or group sequential designs [11]. For example,
Chen [7] extended Simon's designs to three stages and
found a mean reduction in sample size of only 10% with
the addition of an extra stage.
When the response of interest is based on a time to event
outcome (e.g., one-year survival), censoring becomes an
issue during the interim analysis, as it is unclear how sub-
jects without sufficient follow-up should be handled. The
simple proportion of all subjects surviving the required
time is a biased estimate of the survival probability if
some subjects have incomplete follow-up, and restricting
the estimate to those subjects followed for the required
time results in an inefficient estimate. On the other hand,
suspending accrual while all the subjects are followed the
required length of time is impractical. Long trial suspen-
sions can ruin a trial's momentum, increase study length,
and increase costs, and it is potentially unclear how to
treat new subjects during the suspension.
Example
In 1998, investigators in the Comprehensive Cancer Cent-
er of Wake Forest University wanted to design a phase II
study to assess the activity a new chemo-radiation combi-
nation for patients with resectable pancreatic cancer. Pan-
creatic cancer is the most deadly of all the major cancers.
When this trial was planned, 29,000 new cases of pancre-
atic cancer and 28,900 deaths from the disease were ex-
pected in the United States [12]. Patients with resectable
pancreatic cancer have a better prognosis than those with
unresectable disease, but the long-term outlook for these
patients is still bleak. Investigators felt that Gemcitabine,
a radiation sensitizer that had shown activity in pancreatic
cancer [13–16], combined with external beam radiation,
could improve the prognosis of these patients. Since the
tumors were resected in these patients, objective tumor re-
sponse was not a possible outcome, and one-year survival
was chosen as a clinically meaningful outcome. The inves-
tigators decided that the treatment would be considered
unsuccessful if the one-year survival was 35% or less, and
it would be considered active enough to pursue further if
the one-year survival was 50% or greater.
The fixed sample size required for a single-stage study to
test this hypothesis, based on an exact binomial test,
would be 72. If 31 or more of the patients live longer than
one year, the null hypothesis would be rejected. This de-
sign has type I and II errors of .096 and .097, respectively.
Assuming accrual of 24 patients per year (for a duration of
accrual of 3 years), each patient would be followed until
failure or for a maximum of one year and the single anal-
ysis would be done at 4 years.
Now suppose we would like to do one interim analysis
during the course of the study. As mentioned previously,
Simon's [4] two-stage designs could be used to accom-
plish this goal. Thirty-four patients would be needed dur-
ing the first stage. Each of these patients would be
followed until failure or for a maximum of one year. After
each of the original 34 patients has been followed for one
year, the interim analysis would be done. If 13 or more pa-
tients live one year, the study would continue until a total
of 81 patients had been accrued. All patients would then
be followed until failure or for one year. If 34 or more pa-
tients live one year then the null hypothesis would be re-
jected. This design has a 59% chance of stopping at the
interim analysis under the null hypothesis. Characteristics
of this design are shown in Table 1. The expected sample
size under H0 is 53.2 (or 74% of the fixed sample value).
The expected and maximum study lengths are 3.63 and
5.38 years, respectively, (or 91% and 134% of the fixed
sample values). As mentioned earlier, the problem with
this design is that accrual is suspended for one year while
those initially accrued are followed to determine their sta-
tus. This trial suspension is inconvenient and can lead to
a long study (in this example the maximum study length
is 5.38 years compared to 4 years for the fixed sample de-
sign). These problems are exacerbated for longer
suspensions.
One might be tempted to use Simon's design, but to ac-
crue additional patients while the initial 34 are followed.
Characteristics for this design are also shown in Table 1.
For our example, 24 additional patients would be accruedBMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/6
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while the first 34 are being followed, and the trial would
have an expected sample size under H0 of 67.4 (or 94% of
the fixed sample value). The expected and maximum
study lengths would be 3.22 and 4.38 years, respectively
(or 80% and 109% of the fixed sample values). One sees
that accruing additional patients while the initial patients
are followed results in a greater expected sample size, but
shorter expected and maximum total study lengths. The
two main problems with this design are 1) information
from patients who have been followed less than one year
during the interim analysis is ignored, and 2) information
collected from the additional patients is potentially never
used. Additionally, if accrual is fast, the total required re-
cruitment could be completed by the time of the interim
review, possibly resulting in more patients than necessary
being treated with, what turns out to be, an ineffective reg-
imen. Note that Herndon [9] proposes a hybrid phase II
design that allows for interim accrual but uses informa-
tion collected on all patients by delaying the decision to
stop the trial until all data are reviewed.
Several researchers have proposed using the Kaplan-Meier
[17] or Nelson-Aalen [18] estimates of the survival proba-
bility during interim analyses to account for the informa-
tion available from those with partial follow-up without
necessitating trial suspension. Jennison and Turnbull [19]
give an example of assessing the effect of a drug on the
mother to infant HIV transmission rate among HIV infect-
ed breast-feeding mothers, where the proportion of in-
fants infection-free at two years would be a meaningful
outcome. They suggest monitoring such a trial using Kap-
lan-Meier [17] estimates and the spending function ap-
proach originally described by Lan and DeMets [20]. Lin
et al [21] discuss the design of a study in young children
with Wilms cancer for which two-year relapse-free survival
is the primary outcome, and Nelson-Aalen [18] estimates
are used during the interim analyses.
In the next section, we apply results presented by Lin et al
[21] to show how to design efficient phase II studies for
monitoring survival probabilities without the aforemen-
tioned drawbacks. We develop designs that minimize ei-
ther the expected duration of accrual or the expected total
study length under H0. We choose optimal designs under
the null hypothesis since we want to minimize the
number of patients treated with an ineffective regimen.
Numerical results are presented to illustrate the effect of
different choices for the design parameters, including the
type I and II errors and the duration of accrual (or, alter-
natively, the accrual rate). We illustrate these methods in
detail for our particular trial and follow with a discussion
of possible limitations and extensions.
Methods
Lin et al [21] derived the asymptotic joint distribution of
the Nelson-Aalen [18] estimates of survival calculated at
different calendar times during a study and applied the re-
sults to longitudinally monitor a National Wilms Tumor
Study Group protocol. A brief summary of their relevant
results is given below. Following their notation, assume n
patients are accrued to a trial at times Y1,...,Yn. Let T1,...,Tn
denote the failure times and C1,...,Cn the censoring times
since study entry. At time t, we observe for each individual
either a failure time or a censoring time and an indicator
specifying which. That is, we observe the time Xi(t) =
min(Ti,Ci, max (0, t - Yi))) and the failure indicator ∆i(t) =
I{Ti ≤ min(Ci, max(0,(t - Yi)))}. Let   de-
note the estimate of x-year survival at time t, based on the
Nelson-Aalen [18] estimate of the cumulative hazard
function, Λ(x;t):
The process,  , x <t, is asymptotically
Gaussian, which, assuming constant accrual and no loss
to follow-up, has variance function
Table 1: Characteristics of Single Stage, Simon Two-Stage, and Optimal Two-Stage Designs *
Design ESS (%) MDA (%) ETSL (%) MTSL (%)
Single Stage 72.0 (100) 3.00 (100) 4.00 (100) 4.00 (100)
Simon – no interim accrual 53.2 (74) 3.38 (112) 3.63 (91) 5.38 (134)
Simon – interim accrual 67.4 (94) 3.38 (112) 3.22 (80) 4.38 (109)
Proposed – minimize ETSL 63.5 (88) 3.44 (115) 3.00 (75) 4.44 (111)
Proposed – minimize EDA 62.0 (86) 3.27 (109) 3.08 (77) 4.27 (107)
* ESS is the expected sample size; MDA is the maximum duration of accrual; ETSL and MTSL are the expected and maximum total study length, 
respectively. Expected values are calculated under the null hypothesis; percentages are calculated relative to the single stage values.
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where λ(u) is the hazard function and MDA is the maxi-
mum duration of accrual. Lin et al [21] recommend as-
sessing the hypothesis H0: S(x) = S0(x) at time t using the
asymptotically standard normal test statistic
where
Let I(x;ti) denote the information available for estimating
S(x) at time ti. The joint distribution of Z(x;t) calculated
over the course of the study is multivariate normal with
correlations given by  , where ti ≤ tj.
Now consider the design of a two-stage phase II trial for
testing H0: S(x*) = S0(x*), where x* denotes the survival
time of interest and S(.) denotes the survival function
which can be estimated as described above (or by using
the Kaplan-Meier estimator). As illustrated below, let t1
and t2 denote the duration of the first and second accrual
periods, and let MTSL denote the maximum total study
length (MTSL = t1 + t2 + x*).
We will use the following notation:
x* = survival time of interest
ti = duration of accrual for the ith stage
ni = sample size accrued during the ith stage; n = n1 + n2
ν = constant rate of accrual
Ps = probability of stopping at t1
DA = duration of accrual
EDA = expected duration of accrual = t1 + (1 - Ps)t2, calcu-
lated under the null hypothesis
ESS = expected sample size = n1 + (1 - Ps)n2 = νEDA, cal-
culated under the null hypothesis
MDA = maximum duration of accrual = t1 + t2
ETSL = expected total study length = t1 + (1 - Ps)(t2 + x*),
calculated under the null hypothesis
MTSL = maximum total study length = t1 + t2+ x*
I1 = information available at t1
Imax = information available at MTSL
A two-stage design proceeds as follows.
Stage 1. Accrue n1 patients between time 0 and time t1.
Each patient will be followed until failure or for x* years
or until time t1, whichever is less. Calculate Z1(x*;t1) as
given in (2). If Z1(x*;t1) < C1 stop the study and "accept"
H0; otherwise, continue to the next stage.
Stage 2. Accrue n2 additional patients between times t1
and t1 + t2 (= MDA). Follow all patients until failure or for
x* years, calculate Z2(x*;MTSL), and reject H0  if
Z2(x*;MTSL) > C2.
An interim analysis could be done anytime after x* years
and before time MTSL. The expected duration of accrual
(EDA) under the null hypothesis is given by EDA = t1 + (1
- Ps)t2, where Ps = Φ(C1) and Φ(.) denotes the standard
normal distribution function. The expected total study
length (ETSL) under the null hypothesis is given by ETSL
= t1 + (1 - Ps)(t2 + x*). The maximum amount of informa-
tion for estimating Λ(x*), (Imax), occurs whenever t ≥ MT-
SL. The joint distribution of Z1 and Z2 is bivariate normal
with correlation  .
During the design stage, estimates of the information as a
function of time can be obtained by making assumptions
regarding the expected survival distribution. Once the sur-
vival distribution is specified, the expected information at
any time (I(x*;t) = 1/σ2(x*;t)) can be easily obtained by
numerically evaluating equation 1. The Weibull distribu-
tion is a flexible and simple choice, as the survival distri-
butions are completely specified by the null and
alternative survival probabilities for any given shape
parameter.
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For two-stage phase II designs for survival probabilities,
there are four unknowns – n1 or t1, n2 or t2, C1, and C2 –
and two constraints (type I and II errors). We assume the
accrual rate is fixed. As there are more unknowns than
constraints, there will be an infinite number of solutions.
We will choose those solutions that minimize either the
expected duration of accrual (i.e., expected sample size) or
the expected total study length under the null hypothesis.
Note that this is the same paradigm as used by Simon [4]
in selecting optimal designs for binomial outcomes,
where he only allows early acceptance of the null hypoth-
esis and minimizes the expected sample size under the
null hypothesis. Specifically, we choose to minimize the
EDA or the ETSL given that B(C1,C2,ρ) = α and B(C1-
ρu,C2- u, ρ) = 1 - β, where u = n1/2(µ - µ0)/σ, µ and σ are
the mean and standard deviation of the test statistic, and
B(C1,C2,ρ) denotes the bivariate normal probability that
Z1 >C1 and Z2 >C2, given a correlation between Z1 and Z2
of ρ. Numerical integration of the bivariate normal distri-
bution is accomplished using a double precision Fortran
function written by Donnelly [22]. For initially chosen
values for C2 and ρ, values of C1 and n are found to satisfy
the two error constraints. The parameter values that result
in an optimal design are found by iterating over C2 and ρ
using a combination golden-section search and parabolic
interpolation minimization routine described by Brent
[23]. A given choice of n and ρ corresponds to a specific t1,
which is obtained by solving equation 1 under the null
hypothesis. This, in turn, corresponds to another ρ under
the alternative hypothesis, obtained by solving equation 1
under the alternative specifications. This latter ρ is used in
calculating the sample size (or duration of accrual) that
satisfies the type II error constraint. For practical purposes
this step is probably unnecessary since the correlation is
very similar under the null and alternative hypotheses,
even though the information is different at each stage un-
der the two hypotheses. Fortran code implementing this
algorithm is available from the first author upon request.
Run times vary between 5 and 10 minutes on an IBM
compatible Pentium 3 600 MHz PC; the run time can be
decreased by decreasing the precision specified in the
program.
Results
Application
Consider the example mentioned earlier. That is, suppose
we would like to design a phase II study to assess the ef-
fectiveness of adjuvant Gemcitabine and external beam
radiation for the treatment of patients with resectable
pancreatic cancer. The principal outcome measure used to
quantify treatment effect will be one-year survival, and we
will test the null hypothesis that one-year survival is 35%
or less. We desire to have 90% power at an alternative one-
year survival of 50% for testing this hypothesis at the 10%
one-sided level of significance.
We use the methods described above to develop two-stage
designs that minimize either the duration of accrual or the
expected total study length under the null hypothesis. An
interim analysis could be done anytime after one year un-
til the end of the study. We assume survival follows a
Weibull distribution with a shape parameter of one and a
scale parameter of 1.0498 (since S(1) = .35 under H0). Ad-
ditionally, we assume accrual of 24 patients per year. At
this point in the development of the study it might be use-
ful to consider the optimal designs for various interim
analysis times. Characteristics of some of these designs are
shown in Table 2. The design that minimizes the expected
total study length has an interim analysis after 2.2 years.
At that time, one calculates Z1(x*;t1) as described above.
If Z1(x*;t1) < .375 then the study is stopped and the null
hypothesis 'accepted'. Otherwise, accrual continues for
1.2 additional years, all patients are followed until failure
or for one year, and the null hypothesis is rejected if
Z2(x*;MTSL) > 1.172. This design has an expected sample
size of 63.5 (88% of the fixed sample value) and an ex-
pected total study length of 3.0 years (75% of the fixed
sample value). The design that minimizes the expected
duration of accrual has an interim analysis after 1.9 years.
At that time, one calculates Z1(x*;t1) as described above.
If Z1(x*;t1) < .004 then the study is stopped and the null
hypothesis 'accepted'. Otherwise, accrual continues for
1.4 additional years, all patients are followed until failure
or for one year, and the null hypothesis is rejected if
Z2(x*;MTSL) > 1.220. This design has an expected sample
size of 62 (86% of the fixed sample value) and an expect-
ed study length of 3.1 years (77% of the fixed sample val-
ue). The expected and maximum duration of accrual and
total study lengths for these designs are also listed in Table
1 for comparison with the single stage and Simon two-
stage designs. One notes that both of the optimal designs
have a smaller ETSL and EDA than one would get from us-
ing a Simon design with interim accrual. In addition, they
have a smaller ETSL and MTSL than one would get from
using a Simon design without interim accrual. Of course,
the latter Simon design would have a smaller expected
sample size since it is optimal in that respect.
Figure 1 shows results for optimal designs chosen to min-
imize the ETSL under H0 for a range of interim analysis
times. In Figure 1, one sees that the ETSL is fairly flat for
optimal designs with interim analyses between 1.8 and
2.8 years, so any design chosen with an interim analysis
between these two times will be close to optimal. Thus, a
more feasible design might be to have the interim analysis
at 2.6 years since the expected total study length for this
design is close to optimal and the maximum duration of
accrual and the maximum study length are smaller than
those for the overall optimal design.BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/6
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Misspecification of Survival Distributions and Accrual
Although the test used in assessing the survival probabili-
ties is nonparametric, the choice of a particular design
during the planning stage of a trial depends on specifica-
tion of the survival distribution as well as the accrual rate.
Misspecifying these parameters can lead to nonoptimal
designs with incorrect type I and II errors. For example,
consider the Weibull survival distributions shown in Fig-
ure 2 with scale parameters equal to those of the exponen-
tial distributions (under the null hypothesis in the figure)
from the example above and shape parameters ranging
from 0.25 (i.e., events happening earlier on relative to the
exponential) to 4.0 (i.e., events happening later). Were we
to have designed the trial as above assuming exponential
survival (shape parameter = 1), and survival actually fol-
lowed one of the other Weibull distributions, then we
would be getting information faster (shape < 1) or slower
(shape > 1) than anticipated, resulting in a larger or small-
er correlation and increased or decreased α and 1 - β.
Table 3 illustrates the degree to which α and 1 - β are af-
fected by misspecification of the survival distributions, as-
suming the design is used as given and not changed before
or after the interim review. It can be seen that misspecifi-
cation of the survival distribution actually has little effect
on α and 1 - β, with α ranging from .095 to .106 and 1 - β
ranging from .880 to .918 as the shape parameter varies
from 4.0 to 0.25.
Misspecifying the accrual rate has a much greater impact.
Clearly, if accrual were slower or faster than expected, then
one would have a lesser or greater proportion of the data
at the planned interim analysis. Table 4 shows the effect
of misspecifying the accrual rate on the operating charac-
teristics of the design that minimizes the expected total
study length. Three scenarios are considered. First we
consider what would happen if analyses are done at the
planned times, i.e. t1 and MTSL. Under this scenario, the
correlation structure is unchanged so there is no effect on
the type I error. However, the effect on the power is sub-
stantial since the sample size is much smaller or larger
than planned. As the actual accrual decreases relative to
the anticipated accrual, the power decreases whereas it in-
creases as the actual accrual increases relative to the antic-
ipated accrual. Under the second scenario, the first
analysis is conducted at t1. The second analysis is conduct-
ed one year after t1 or after n patients are accrued, which-
ever is later. Here, the correlation structure and the sample
sizes are both affected by the accrual rate, and we see that
both α and 1 - β decrease as the actual accrual decreases
relative to the anticipated accrual, whereas both increase
as the actual accrual increases relative to the anticipated
accrual. Under the third scenario, we conduct analyses af-
ter n1 and n patients have been accrued. Here only the cor-
relation structure is affected by the accrual rate. That is, I1
depends on how long each of the n1 subjects is followed.
A slower accrual means each subject is followed longer, so
I1 and the correlation increase. Under this scenario, the ef-
fects of misspecifying the accrual rate on α and 1 - β are
less substantial. Both α and 1 - β increase as the actual ac-
crual decreases relative to the anticipated accrual, whereas
both decrease as the actual accrual increases relative to the
anticipated accrual.
General Results
The design parameters (C1, C2, t1, and t2) and perform-
ance (as quantified by EDA and ETSL relative to the fixed
sample values, DA and TSL, respectively) of the phase II
designs depend on α, β, x*, and DA (or alternatively, the
rate of accrual), and survival under the null and alterna-
tive hypotheses. Table 5 provides optimal design parame-
ters (for minimizing EDA  or  ETSL) and design
characteristics for α = β = .05 and .10 for our particular de-
sign of interest, assuming survival will follow a Weibull
Table 2: Optimal (under H0) two-stage parameters for testing H0: S(1) ≤ .35 vs H1: S(1) > .35. Power is 90% at S(1) = .5 *
Minimized t1 C1 C2 I1/Imax EDA (%) MDA(%) ETSL (%) MTSL (%)
ETSL 1.8 .137 1.164 .31 2.65 (88) 3.71 (124) 3.10 (77) 4.71 (118)
2.0 .270 1.164 .38 2.63 (88) 3.59 (120) 3.02 (76) 4.59 (115)
2.2 @ .375 1.172 .46 2.65 (88) 3.44 (115) 3.00 (75) 4.44 (111)
2.4 .464 1.184 .53 2.70 (90) 3.32 (111) 3.02 (75) 4.32 (108)
2.6 .550 1.198 .61 2.78 (93) 3.22 (107) 3.07 (77) 4.22 (105)
EDA 1.5 -.313 1.223 .25 2.66 (89) 3.36 (112) 3.28 (82) 4.36 (109)
1.7 -.125 1.218 .31 2.60 (87) 3.33 (111) 3.15 (79) 4.33 (108)
1.9 @ .004 1.220 .38 2.58 (86) 3.27 (109) 3.08 (77) 4.27 (107)
2.1 .109 1.227 .46 2.60 (87) 3.20 (107) 3.06 (76) 4.20 (105)
2.3 .189 1.237 .53 2.65 (88) 3.13 (104) 3.08 (77) 4.13 (103)
* t1 is the time of the first interim review; C1 and C2 are the cutpoints for acceptance at the first stage and rejection at the second stage; EDA and 
MDA are the expected and maximum duration of accrual; and ETSL and MTSL are the expected and maximum total study length. Expected values 
are calculated under the null hypothesis; percentages are calculated relative to the single stage values. @ optimal designBMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/6
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distribution with shape parameter equal to one. Note that
the designs depend on the survival time of interest (x*)
and the fixed duration of accrual (DA) in a relative
manner. That is, the same design is obtained for assessing
2-year survival when the fixed sample duration of accrual
is 4 years as that for assessing 1-year survival when the
fixed sample duration of accrual is 2 years. Designs are
given for DA/x* ranging from 1.5 (e.g., x* = 2 and DA = 3)
to 4 (e.g., x* = 1 and DA = 4). Several observations are
obvious. As the duration of accrual decreases (accrual rate
increases), the advantages of doing an interim analysis
become less pronounced. Interim analyses done after the
accrual period would not decrease the EDA but could de-
crease the ETSL. If all patients are accrued prior to x*, there
can be no reduction in the expected sample size by having
an interim analysis, and the reductions in expected total
study length become smaller. Clearly, if all patients are ac-
crued at once, there can be no interim analysis and the op-
timal design is the fixed sample design.
As the duration of accrual increases relative to x*, the in-
terim analysis is done earlier relative to the fixed sample
duration of accrual. As the duration of accrual approaches
infinity, the optimal design becomes the Simon design
(or, in our case, the normal approximation to the Simon
design) since it becomes increasingly likely that each pa-
tient reaches his or her end point before the next patient
is accrued. Designs optimized to minimize the EDA have
their interim analyses earlier than the respective designs
optimized to minimize the ETSL. This difference becomes
Figure 1
Relative expected and maximum duration of accrual (DA) and total study length (TSL) for designs that mini-
mize the expected total study length (ETSL).
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Figure 2
Weibull survival curves under the null hypothesis
Table 3: Characteristics of Optimal (for ETSL) Design Assuming Misspecification of the Survival Distributions
Weibull Shape Parameter α 1-β
0.25 .106 .918
0.50 .103 .910
0.75 .101 .904
1.00 .100 .900
2.00 .097 .889
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smaller as the duration of accrual increases. As DA/x* in-
creases, ρ decreases slightly for designs that minimize the
ETSL but increases for designs that minimize the EDA.
One observes that the maximum sample size is typically
15–16% greater than the fixed sample size, regardless of
the design parameters for designs that minimize the ETSL.
The maximum sample size is smaller and increases as DA/
x* increases for designs that minimize the EDA. We de-
rived results similar to those shown in Table 5 for other
choices of survival under the null and alternative hypoth-
eses (results not shown). One notes that neither the de-
signs which minimize the ETSL  nor the ones which
minimize the EDA are substantially affected by the choice
of survival probabilities under the null and alternative hy-
potheses, for constant values of DA/x*.
Simulations
The designs given in the Table 5 were derived assuming
the test statistics are asymptotically normally distributed.
However, the sample sizes in most phase II trials are rela-
tively small, especially during the interim analysis, mak-
ing normal approximations suspect. We performed
Table 4: Characteristics of Optimal (for ETSL) Design Assuming Misspecification of Accrual
Scenario 1* Scenario 2* Scenario 3*
Actual/Anticipated Accrual α 1-βα 1 - βα1 - β
0.25 .1 .512 .070 .687 .109 .924
0.50 .1 .711 .082 .800 .106 .918
1.00 .1 .900 .100 .900 .100 .900
1.50 .1 .963 .114 .934 .092 .863
2.00 .1 .986 .115 .970 .079 .779
* Scenario 1 – Analysis at t1 and MTSL ; Scenario 2 – Analysis at t1 and one year after t1 or one year after accruing n patients, whichever is later; Sce-
nario 3 – Analysis after accrual of n1 patients and one year after accruing n patients.
Table 5: Optimal two-stage parameters for designs that minimize either the ETSL (top line) or the EDA (bottom line) for testing H0: 
S(1) ≤ .35. Power is specified for S(1) = .5.#
α 1 - β DA/x* t1 C1 C2 I1/Imax EDA MDA ETSL MTSL
.1 .9 1.50 1.01 .488 1.154 .49 1.05 1.15 .76 1.09
.81 -.489 1.257 .32 .96 1.03 .85 1.02
1.75 .93 .457 1.159 .48 1.00 1.15 .76 1.10
.76 -.291 1.245 .34 .94 1.05 .82 1.03
2 .87 .434 1.163 .47 .96 1.15 .75 1.10
.72 -.179 1.237 .36 .92 1.06 .80 1.04
3 .74 .375 1.172 .46 .88 1.15 .75 1.11
.63 .004 1.220 .38 .86 1.09 .77 1.07
4 .67 .346 1.176 .45 .84 1.15 .75 1.12
.59 .073 1.212 .39 .83 1.10 .76 1.08
.05 .95 1.50 .99 .680 1.536 .46 1.03 1.17 .72 1.10
.81 -.274 1.622 .32 .95 1.04 .81 1.02
1.75 .91 .648 1.541 .46 .98 1.16 .72 1.10
.75 -.084 1.612 .34 .92 1.06 .78 1.04
2 .85 .624 1.545 .45 .94 1.16 .71 1.11
.72 .024 1.605 .35 .89 1.07 .76 1.05
3 .72 .563 1.553 .44 .85 1.16 .71 1.12
.63 .202 1.591 .38 .83 1.10 .72 1.08
4 .66 .531 1.557 .44 .80 1.15 .70 1.12
.59 .266 1.586 .39 .79 1.11 .71 1.09
# DA is the fixed sample duration of accrual; x* is the survival time of interest; t1 is the time of the first interim review; C1 and C2 are the cutpoints 
for acceptance at the first stage and rejection at the second stage; I1 and Imax are the information available at the interim and final reviews; EDA and 
MDA are the expected and maximum duration of accrual relative to the single stage values; and ETSL and MTSL are the expected and maximum 
total study length relative to the single stage values. Expected values are calculated under the null hypothesis.BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/6
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simulations, using one million replications for each of the
designs shown in Table 5, to see how close these designs
came to desired type I and II errors. Fixed sample sizes
were calculated based on the exact binomial distribution,
and the sample sizes at each stage of the two-stage designs
were determined by multiplying the fixed sample size by
t1 and MDA from Table 5 (which are presented there rela-
tive to the fixed sample duration of accrual). These sample
sizes were increased to the nearest integers. For the exam-
ple discussed above, 72 patients is the fixed sample size,
so for a 3 year duration of accrual (i.e., accrual rate of 24
per year), the sample size needed at the first stage is
ceil(72 * .736) = 53 and the maximum sample size is
ceil(72 * 1.148) = 83. The simulations were done fixing
interim and final sample sizes to these values. Random
entry and survival times were generated based on the sur-
vival proportions under the null and alternative hypothe-
ses for patients during the first and second stage (if
needed), and test statistics were calculated as described
earlier and compared to the critical values given in the ta-
ble. Results of the simulations are shown in Table 6. The
realized type I and II errors are reasonably close to the de-
sired values, and, as expected, are closer for the designs
with smaller α and β (larger sample size). It is likely that
designs developed for assessing larger differences between
the null and alternative hypotheses (thus requiring a
smaller sample size) would not be as close. Due to the dis-
creteness of the test statistic at the final stage, small chang-
es in the sample size can markedly affect the actual type I
and II errors.
Discussion
In many phase II cancer trials, activity might be quantified
by a time to event variable such as remission-free or
overall survival, and the outcome might be a survival
probability such as the proportion of patients remission-
free or alive at one or two years. It could be that this is the
primary outcome of interest due to clinical relevance or it
might be that tumor response, the typical outcome in
phase II cancer trials, is not an option as all disease may
have been irradiated or removed during surgery or the tri-
al may be done only in patients who have experienced a
complete response. Although designs developed for mon-
itoring binomial proportions or modifications of these as
described by Herndon [9] could also be used for these
outcomes, they are not optimal. We have shown how re-
sults described by Lin et al [21] could be used to design ef-
ficient phase II trials for monitoring survival probabilities.
We presented designs that minimized either the expected
duration of accrual or the expected total study length un-
der the null hypothesis. The costs of these designs are
maximum sample sizes and total study lengths that are
greater than the fixed sample values. However, the maxi-
mum duration of accrual and total study length are
reached fairly quickly and then decrease with increasing
time to the interim analysis. By considering all possible
designs, one can choose a design that is almost optimal
but which has a smaller sample size and maximum total
study length than that of the fully optimal design.
The frequentist approach presented here represents one
possible strategy for monitoring survival probabilities in a
phase II trial. Other researchers have proposed rather ele-
gant Bayesian approaches to this problem. Follman and
Albert [24] use a Dirichlet prior distribution for describing
the probabilities of failure at discrete times. They show
that the posterior distribution incorporating censored
data is a mixture of Dirichlets, and they use simulations to
estimate the posterior probability that an event rate ex-
ceeds some threshold. Cheung and Thall [25] present a
method for monitoring survival probabilities based on an
approximate posterior, and they apply stopping rules de-
scribed in Thall and Simon [6] based on the approximate
probabilities. In addition, they extend their methods to
the more complicated case of composite events. Both of
these methods have the advantage that they can be ap-
plied continuously.
Table 6: Realized α and 1 - β using simulations of the optimal designs for testing H0: S(1) ≤ .35. Power is specified for S(1) = .5.
Desired α = .1, 1 - β = .9 Desired α = .05, 1 - β = .95
ETSL EDA ETSL EDA
DA/x* α 1 - βα1 - βα1 - βα1 - β
1.50 .103 .909 .100 .907 .049 .953 .043 .948
1.75 .104 .909 .114 .918 .049 .954 .045 .951
2 .126 .919 .089 .898 .050 .954 .051 .955
3 .092 .904 .116 .918 .045 .952 .059 .961
4 .092 .903 .091 .903 .045 .954 .048 .955BMC Medical Research Methodology 2003, 3 http://www.biomedcentral.com/1471-2288/3/6
Page 11 of 12
(page number not for citation purposes)
Another approach to the design of phase II trials for mon-
itoring survival probabilities would be to use parametric
methods. The survival probability at a given time would
be a function of the parameters of the parametric model.
For example, assuming an exponential model, monitor-
ing a survival probability at a given time is equivalent to
monitoring the hazard parameter. Methods proposed by
Case and Morgan [26] could then be used to obtain opti-
mal durations of accrual and follow-up. This approach
has the advantage of using events that occur before or after
the time of interest, but the disadvantage of relying on a
specific model.
In the designs discussed above, we assumed a parametric
distribution to obtain estimates of the information over
time. Were we to have access to data or simply the Kaplan-
Meier estimate of the survival distribution from a previous
trial, we could use those data to obtain a nonparametric
estimate of the information using equation (3). In that
equation, the denominator would need to be multiplied
by min[(t  -  Xi)/MDA,1]. This fully nonparametric ap-
proach has the conceptual advantage that when we design
a study to compare nonparametric estimates of survival
distributions, we frequently do not want to make assump-
tions about the form of S(.). Although one would like to
know S(.) with certainty in planning a study, often we are
faced with an estimate of a summary statistic such as a per-
centile, median, or mean and maybe an idea of the shape
from a Kaplan-Meier plot without access to the data.
Sometimes we have the data from a previous study but do
not have confidence that the population is relevant to the
planned study. Often the choice of developing a design
using the parametric or nonparametric approach will de-
pend on the existence of previous raw data and, if such
data exist, our relative confidence in the parametric as-
sumptions versus the applicability of the population in
the previous study.
Although the approach described above is applicable
when the duration of accrual is long relative to the surviv-
al time of interest, it is not practical when the duration of
accrual is short (say less than 1.5 times the survival time
of interest). This is because there is little information
available for estimating the survival probability before
most of the patients are accrued to the study. If the accrual
period is less than the time of interest, there is no design
that leads to an expected duration of accrual that is less
than the fixed sample value. In our experience of doing
phase II trials in a single institution, it has been rare that
fast accrual would have limited the applicability of these
designs. However, it could be more of a problem with
multicenter or cooperative group trials. A possible solu-
tion includes monitoring a different (earlier) time during
the interim analysis as Lin et al [21] did in their example.
Unfortunately, the connection with the primary end point
of interest is not always clear.
Misspecification of the accrual rate can have a major effect
on the operating characteristics of these designs. The mis-
specification of survival during the design phase has much
less impact on the type I and II errors. However, it is clear
that one needs to monitor the ongoing accrual (as is typi-
cally done in clinical trials) and make modifications to the
design once the accrual rate is ascertained. The ultimate
critical values can be modified once the actual estimate of
the information is obtained during the interim analysis,
but this strategy should result in fairly efficient designs.
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